scholarly journals Neuromuscular Electrostimulation as a New Therapeutic Option to Improve Radio-cephalic Arteriovenous Fistula Maturation in End Stage Chronic Kidney Disease Patients

2019 ◽  
Vol 58 (6) ◽  
pp. e455-e457
Author(s):  
Lucia Martinez ◽  
Vicent Esteve ◽  
Montserrat Yeste ◽  
Ezequiel Paredes ◽  
Secundino Llagostera
2018 ◽  
Vol 20 (1) ◽  
pp. 46-51
Author(s):  
Weng Jun Tang ◽  
Azreen Syazril Adnan ◽  
Md Salzihan Md Salleh ◽  
Arman Zaharil Mat Saad

Introduction: A functioning and reliable arteriovenous fistula is a lifeline for individuals suffering from chronic kidney disease. The success and failure to arteriovenous fistula maturation have been frequently related to patient and surgeon factors. Method: In total, 138 participants with stage IV and V chronic kidney disease were included in this prospective observational study. Preoperative vascular mapping using ultrasound was performed to evaluate the condition and size of the vessels to fulfil the inclusion criteria. Intraoperatively, the vessel size was measured prior to anastomosis under magnified view. A specimen from the arterial wall of 5 mm in diameter was obtained from the arterotomy for histopathology assessment. Arteriovenous maturation was assessed at 6 weeks with the guidance of the ultrasound criteria of rule of sixes. Results: From the total of 138 participants, 110 participants (79.7%) had matured arteriovenous fistula in 6 weeks. The mean size of the artery measured intraoperatively was 3.82 ± 1.33 mm and the vein was 4.05 ± 1.20 mm. Microcalcification in the arterial media which was hypothesised to be the cause of the arteriovenous fistula failure was insignificant, with a p value of 0.115. Despite having atherosclerosis in the artery, 83.3% of the arteriovenous fistula matured. Conclusion: Microcalcification and atherosclerosis are frequently seen in the arteries of chronic kidney disease patients, but they do not explain arteriovenous fistula non-maturation.


PLoS ONE ◽  
2016 ◽  
Vol 11 (1) ◽  
pp. e0146212 ◽  
Author(s):  
Irma L. Geenen ◽  
Felix F. Kolk ◽  
Daniel G. Molin ◽  
Allard Wagenaar ◽  
Mathijs G. Compeer ◽  
...  

2019 ◽  
Vol 21 (6) ◽  
pp. 810-817 ◽  
Author(s):  
Haimanot Wasse ◽  
Alejandro C Alvarez ◽  
Debbie Brouwer-Maier ◽  
Jeffrey E Hull ◽  
Saravanan Balamuthusamy ◽  
...  

End-stage kidney disease patients who are candidates for surgical arteriovenous fistula creation commonly experience obstacles to a functional surgical arteriovenous fistula, including protracted wait time for creation, poor maturation, and surgical arteriovenous fistula dysfunction that can result in significant patient morbidity. The recent approval of two endovascular devices designed to create a percutaneous arteriovenous fistula enables arteriovenous fistula creation to be placed in the hands of interventionalists, thereby increasing the number of arteriovenous fistula providers, reducing wait times, and allowing the patient to avoid surgery. Moreover, current studies demonstrate that patients with percutaneous arteriovenous fistula experience improved time to arteriovenous fistula maturation. Yet, in order to realize the potential advantages of percutaneous arteriovenous fistula creation within our hemodialysis patient population, it is critical to select appropriate patients, ensure adequate patient and dialysis unit education, and provide sufficient instruction in percutaneous arteriovenous fistula cannulation and monitoring. In this White Paper by the American Society of Diagnostic and Interventional Nephrology, experts in interventional nephrology, surgery, and interventional radiology convened and provide recommendations on the aforementioned elements that are fundamental to a functional percutaneous arteriovenous fistula.


2019 ◽  
Vol 32 (9) ◽  
pp. 858-867 ◽  
Author(s):  
Roy O Mathew ◽  
Jerome Fleg ◽  
Janani Rangaswami ◽  
Bo Cai ◽  
Arif Asif ◽  
...  

AbstractBACKGROUNDCentral arteriovenous fistula (cAVF) has been investigated as a therapeutic measure for treatment-resistant hypertension in patients without advanced chronic kidney disease (CKD). There is considerable experience with the use of AVF for hemodialysis in patients with end-stage renal disease (ESRD). However, there is sparse data on the blood pressure (BP) effects of an AVF among patients with ESRD. We hypothesized that AVF creation would significantly reduce BP compared with patients who did not have an AVF among patients with ESRD before starting hemodialysis.METHODSBPs were compared during the 12 months before hemodialysis initiation in 399 patients with an AVF or AV graft created and 4,696 patients without either.RESULTSAfter propensity score matching 1:2 ratio (AVF to no AVF), repeated measures analysis of variance revealed significant reductions of –1.7 mm Hg systolic and –3.9 mm Hg diastolic BP 12 months in patients after AVF creation; P = 0.025 and P < 0.001, respectively, compared with those with no AVF.CONCLUSIONSThese findings suggest that AVF creation results in modest BP reduction in patients with pre-dialysis ESRD who require AVF for eventual hemodialysis therapy. Preferential diastolic BP reduction suggests that greater work is needed to characterize the ideal patient subset in which to use cAVF for treatment-resistant hypertension in those without advanced CKD.


2018 ◽  
Vol 37 (3) ◽  
pp. 277-286 ◽  
Author(s):  
Muhammad A. Siddiqui ◽  
Suhel Ashraff ◽  
Derek Santos ◽  
Robert Rush ◽  
Thomas Carline ◽  
...  

2020 ◽  
Vol 25 (1) ◽  
pp. 28-34
Author(s):  
Supomo Supomo ◽  
Satya Septia Wahyunigrum ◽  
Aditya Agam Nugraha

Highlights Arterial diameter above 2 mm had an almost 5 times better AVF maturation outcome. Average age of ESRD patients who underwent the AVF procedure was above 50 years. Percentage of AVF maturation was higher in men. Hypertension was the most common comorbid factor in ESRD patients.


Sign in / Sign up

Export Citation Format

Share Document